NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
IntroductionGBA1 variants are significant genetic risk factors for Parkinson's disease (PD). Accurately measuring glucocerebrosidase (GCase) activity is crucial for understanding disease progression and developing targeted therapies. This study aimed to validate strategies for measuring blood GCase activity in patients with GBA1-associated PD (GBA-PD).MethodsWe recruited 25 GBA-PD patients and 27 matched PD patients without GBA1 variants (non-GBA-PD). GCase activity from fresh blood was quantified using the 4-methylumbelliferyl β-D-glucopyranoside leukocyte assay (GCaseRaw). The GCase patient/normal control ratio (GCase ratio) was calculated for consistency. GCase activity in dried blood spot (DBS) specimens (GCaseDBS) and plasma glucosylsphingosine (GluSph) levels were measured using LC-MS/MS. The diagnostic accuracy was assessed using area under the curve (AUC) values.ResultsNo significant differences in demographics or disease characteristics were found between GBA-PD and non-GBA-PD patients. GCase activity was significantly lower in patients with GBA-PD (p r = -0.326; p DiscussionThe relative ratio of GCase activity showed a strong discriminatory potential, distinguishing between GBA-PD and non-GBA-PD.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.